Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
Ajouter des filtres








Gamme d'année
1.
Chinese Medical Journal ; (24): 2560-2566, 2009.
Article Dans Anglais | WPRIM | ID: wpr-307863

Résumé

<p><b>BACKGROUND</b>A five-year follow-up study of intensive multifactorial intervention was undertaken to assess the changes of circulating serum amyloid A (SAA) levels and the incidence of atherosclerosis (AS) in patients with short-duration type 2 diabetes mellitus (T2DM) without macroangiopathy, and whether intensive multifactorial intervention could prevent or at least postpone the occurrence of macroangiopathy.</p><p><b>METHODS</b>Among 150 patients with short-duration T2DM, 75 were assigned to receive conventional outpatient treatment (conventional group) and the others underwent intensive multifactorial integrated therapy targeting hyperglycemia, hypertension, dyslipidemia and received aspirin simultaneously (intensive group).</p><p><b>RESULTS</b>Plasma SAA levels were higher in diabetic patients than those in healthy control subjects, and decreased obviously after intensive multifactorial intervention. The levels of SAA were positively correlated with body mass index (BMI), waist hip ratio (WHR), triglyceride (TG), high sensitive C-reactive protein (hs-CRP) and common carotid intima-media thickness (CC-IMT). The standard-reaching rates of glycemia, blood pressure and lipidemia were significantly higher in intensive group than those of conventional group. The incidence of macroangiopathy decreased by 58.96% in intensive group compared with conventional group.</p><p><b>CONCLUSIONS</b>Intensive multifactorial intervention may significantly reduce the SAA levels and prevent the occurrence of AS in short-duration patients with T2DM. SAA might be one of the risk factors of T2DM combined with AS.</p>


Sujets)
Adulte , Sujet âgé , Femelle , Humains , Mâle , Adulte d'âge moyen , Antihypertenseurs , Pharmacologie , Utilisations thérapeutiques , Glycémie , Métabolisme , Protéine C-réactive , Métabolisme , Diabète de type 2 , Traitement médicamenteux , Métabolisme , Angiopathies diabétiques , Hypoglycémiants , Pharmacologie , Utilisations thérapeutiques , Hypolipémiants , Pharmacologie , Utilisations thérapeutiques , Analyse multifactorielle , Protéine amyloïde A sérique , Métabolisme , Triglycéride , Sang , Tunique moyenne
2.
Chinese Medical Journal ; (24): 1165-1168, 2008.
Article Dans Anglais | WPRIM | ID: wpr-258512

Résumé

<p><b>BACKGROUND</b>Tanis was reported as a putative receptor for serum amyloid A (SAA) involving glucose regulated protein in insulin regulated resistance. It was found to be dysregulated in diabetic rats (Psammomys obesus, Israeli sand rat) and its homologue for humans is SelS/AD-015. The present study analyzed mRNA expression of SelS in omental adipose tissue biopsies from patients with type 2 diabetes mellitus (T2DM), and age- and weight-matched nondiabetic patients, the relationship of SelS mRNA with Homa-IR and serum SAA level.</p><p><b>METHODS</b>Human omental adipose tissues from ten cases of type 2 diabetic patients and twelve cases of nondiabetic individuals were analyzed for the expression level of SelS mRNA by semiquantitative polymerase chain reaction (PCR), Homa-IR estimated by standard formula and SAA level by enzyme-linked immunosorbent assay (ELISA).</p><p><b>RESULTS</b>SelS mRNA expression, Homa-IR and serum SAA were higher in T2DM sufferers than in nondiabetic control group. SelS mRNA level was positively correlated with Homa-IR and SAA level in each group.</p><p><b>CONCLUSIONS</b>SelS protein may be involved in insulin resistance in Chinese with T2DM by acting as the SAA receptor, thus playing an important role in the development of T2DM and atherosclerosis.</p>


Sujets)
Adulte , Sujet âgé , Femelle , Humains , Mâle , Tissu adipeux , Métabolisme , Séquence nucléotidique , Diabète de type 2 , Métabolisme , Insulinorésistance , Protéines membranaires , Génétique , Données de séquences moléculaires , Omentum , Métabolisme , ARN messager , Sélénoprotéines , Génétique , Protéine amyloïde A sérique
SÉLECTION CITATIONS
Détails de la recherche